- Conditions
- Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
- Interventions
- ChemoID Assay, Standard Chemotherapy
- Diagnostic Test · Drug
- Lead sponsor
- Cordgenics, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 1,448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Video consent (high-tech), Video consent (low-tech), FAQ format consent, Standard consent, PDF informed consent document
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 34 Years · Male only
- Enrollment
- 2,405 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cesarean Section, Obstetric Anesthesia
- Interventions
- Intrathecal hydromorphone
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Human Papilloma Virus
- Interventions
- Comprehensive Vaccine Promotion Package
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 11 Years to 12 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Canton, Georgia • Duluth, Georgia • Lawrenceville, Georgia + 3 more
- Conditions
- Gout
- Interventions
- Lesinurad, Placebo, Allopurinol
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 88
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
- Conditions
- UC - Ulcerative Colitis
- Interventions
- Upadacitinib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
- Diagnostic Test · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Hematologic Malignancies
- Interventions
- SLS009, venetoclax, azacitidine
- Drug
- Lead sponsor
- Sellas Life Sciences Group
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more
- Conditions
- Multiple Myeloma
- Interventions
- Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
- Drug · Device
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
- Interventions
- Supplement, Placebo, Expanded Interview, Standard Interview
- Drug · Behavioral
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Pain and Relapse Prevention
- Interventions
- Chronic pain therapeutic interactive voice response (TIVR) system
- Behavioral
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Lung Non-Small Cell Carcinoma, Pleural Disorder
- Interventions
- Porfimer Sodium, Video-Assisted Thoracic Surgery, Photodynamic Therapy, Intraoperative PDT
- Drug · Procedure · Device
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer, Rectal Cancer, Rectal Adenocarcinoma, Colorectal Cancer
- Interventions
- Cabozantinib, Nivolumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- Home Ankle Strengthing Program, Standard of Care
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Metastatic Prostate Cancer
- Interventions
- 18F-DCFPyL-iPSMA, 68Ga-HBED-iPSMA, PET/CT scan
- Drug · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Septic Shock, Acute Kidney Injury
- Interventions
- Standard of Care, Angiotensin II
- Other · Drug
- Lead sponsor
- Alexander Flannery
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Interventions
- Telephone based interview, Survey using a questionnaire., Electronic health record review, Referral
- Behavioral · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
- Interventions
- Glofitamab, Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin, Obinutuzumab:
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Hackensack, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- Low Energy SLT, Standard Energy SLT
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 28
- States / cities
- Laguna Hills, California • Pasadena, California • Sacramento, California + 22 more
- Conditions
- Brain Diseases, Brain Cancer
- Interventions
- Wiersma Head Stabilizer, AlignRT system
- Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obstructive Sleep Apnea, Sleep Apnea, Sleep Apnea, Obstructive, Sleep, Sleep Disorder
- Interventions
- Eszopiclone, Supplemental Oxygen, Continuous Positive Airway Pressure (CPAP)
- Drug · Other · Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Cancer, Melanoma (Skin Cancer), Immunotherapy
- Interventions
- Digital remote monitoring intervention, Usual Care
- Behavioral · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Gastroesophageal Adenocarcinoma
- Interventions
- FLOT, FOLFOX, FOLFIRI, FOLFIRINOX, PACLITAXEL with or without CARBOPLATIN, DOCETAXEL and IRINOTECAN (alone or combined), NIVOLUMAB (alone or when added to a regimen above), PEMBROLIZUMAB (alone or when added to a regimen above), Durvalumab, Trastuzumab
- Combination Product · Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Afatinib, Paclitaxel, Carboplatin, Cisplatin, Intensity Modulated Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Nashville, Tennessee